Media Center

Sandoz launches AirFluSal® Forspiro® in South Korea

Seoul, May 14 2014

Sandoz Korea announces that it is launching today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

​The product was first approved in Denmark in December, 2013 with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania, Bulgaria and South Korea.

“We are pleased to launch AirFluSal® Forspiro® in South Korea. This is a milestone in our strategy of bringing our world class innovative inhaler to patients in Korea,” said Sujun Park, Country Head of Sandoz Korea.

AirFluSal® Forspiro® offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative new inhalation device. The product’s safety, efficacy and equivalence have been proven in multiple clinical trials12.

AirFluSal® Forspiro® was developed at Aeropharm GmbH in Rudolstadt, Germany, Sandoz’ global respiratory Center of Excellence. Sandoz collaborated with UK-based Vectura, a respiratory product development company, in the design and development of the product. The innovative and intuitive to use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.

In order to improve patient experience with inhalation devices, Sandoz collaborated closely with patients during the development of AirFluSal® Forspiro®. The device features an innovative, patient-friendly design, including multiple feedback mechanisms, such as visual control features which help reassure the patient about dosing, simple lever arm to load the dose, clear and accurate dose counter.

South Korea has approved the 50/250 and 50/500 µg dosage forms for the continuous treatment of patients above four years of age with persistent asthma or for symptomatic treatment of COPD.

References

1Kuna, I. Gath, U. Thyroff-Friesinger, S. Jones. Equivalence of fluticasone propionate/salmeterol delivered via new multi-dose dry powder inhaler and accuhaler™ in adolescent and adult asthma. Ajrccm conference.2013.187.1_MeetingAbstracts.A2611

2Sandoz data on file

About Sandoz

Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees across more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).

About Sandoz Korea

Since 2006, Sandoz Korea has launched products in various therapeutic areas, including key therapeutic areas such as the central nervous system, oncology, respiratory and cardiovascular. Major products include Mirtax’, Sandoz Olanzapine, ‘Sandoz Pramipexol’, ‘Sinemet’ in neuropsychiatry, ‘Sandoz Vinorelbine’, ‘Sandoz Paclitaxel’, ‘Sandoz Oxaliplatin’ in oncology, ‘Sandoz Montelukast’, the asthma and allergic rhinitis treatment, which is our major respiratory product, and ‘Imprida’, our major cardiovascular product.

For further information, contact:

Macoll Communication Consulting

Ji-young Kim
+82 2 6915 3042 / +82 10 5293 0714
jiyoung.kim@macoll.com

Jee-min Lee
+82 2 6915 3102 / +82 10 5002 8259
jeemin.lee@macoll.com

Sandoz Global Communications:

Neil Moorhouse
+49 8024 476 2597;
neil.moorhouse@sandoz.com